{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:52:59Z","timestamp":1766908379377,"version":"3.40.5"},"reference-count":44,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2022,8,26]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Approval of the first boronic acid group-containing drug, bortezomib, in 2003 for the\ntreatment of multiple myeloma sparked an increased interest of medicinal chemists in boronic acidbased\ntherapeutics. As a result, another boronic acid moiety-harboring medication, ixazomib, was approved\nin 2015 as a second-generation proteasome inhibitor for multiple myeloma; and dutogliptin is\nunder clinical investigation in combination therapy against myocardial infarction. Moreover, a large\nnumber of novel agents with boronic acid elements in their structure are currently in intensive preclinical\nstudies, allowing us to suppose that at least some of them will enter clinical trials in the near future.\nOn the other hand, only some years after bortezomib approval, direct interactions between its boronic\nacid group and catechol moiety of green tea catechins as well as some other common dietary\nflavonoids like quercetin and myricetin were discovered, leading to the formation of stable cyclic\nboronate esters and abolishing the anticancer activities. Although highly relevant, to date, no reports\non possible co-effects of catechol group-containing flavonoids with new-generation boronic acidbased\ndrugs can be found. However, this issue cannot be ignored, especially considering the abundance\nof catechol moiety-harboring flavonoids in both plant-derived food items as well as over-thecounter\ndietary supplements and herbal products. Therefore, in parallel with the intensified development\nof boronic acid-based drugs, their possible interactions with catechol groups of plant-derived\nflavonoids must also be clarified to provide dietary recommendations to patients for maximizing therapeutic\nbenefits. If concurrently consumed flavonoids can indeed antagonize drug efficacy, it may\npose a real risk to clinical outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009622666220516102235","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:55:20Z","timestamp":1652774120000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of\nBortezomib: What about the other Boronic Acid-based Drugs?"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-2525","authenticated-orcid":true,"given":"Katrin","family":"Sak","sequence":"first","affiliation":[{"name":"NGO Praeventio, Tartu 50407, Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0973-7847.95849","volume":"6","author":"Petrovska B.B.","year":"2012","unstructured":"Petrovska B.B.; Historical review of medicinal plants\u2019 usage. Pharmacogn Rev 2012,6(11),1-5","journal-title":"Pharmacogn Rev"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8748253","volume":"2019","author":"Forni C.","year":"2019","unstructured":"Forni C.; Facchiano F.; Bartoli M.; Pieretti S.; Facchiano A.; D\u2019Arcangelo D.; Norelli S.; Valle G.; Nisini R.; Beninati S.; Tabolacci C.; Jadeja R.N.; Beneficial role of phytochemicals on oxidative stress and age-related diseases. BioMed Res Int 2019,2019","journal-title":"BioMed Res Int"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0973-7847.134247","volume":"8","author":"Sak K.","year":"2014","unstructured":"Sak K.; Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev 2014,8(16),122-146","journal-title":"Pharmacogn Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12937-017-0309-7","volume":"17","author":"Kent K.","year":"2018","unstructured":"Kent K.; Charlton K.E.; Lee S.; Mond J.; Russell J.; Mitchell P.; Flood V.M.; Dietary flavonoid intake in older adults: how many days of dietary assessment are required and what is the impact of seasonality? Nutr J 2018,17(1),7","journal-title":"Nutr J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.3390\/molecules25225243","volume":"25","author":"Ullah A.","year":"2020","unstructured":"Ullah A.; Munir S.; Badshah S.L.; Khan N.; Ghani L.; Poulson B.G.; Emwas A.H.; Jaremko M.; Important flavonoids and their role as a therapeutic agent. Molecules 2020,25(22),5243","journal-title":"Molecules"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajps.2017.08.004","volume":"13","author":"Wang T.Y.","year":"2018","unstructured":"Wang T.Y.; Li Q.; Bi K.S.; Bioactive flavonoids in medicinal plants: Structure, activity and biological fate. Asian J Pharm Sci 2018,13(1),12-23","journal-title":"Asian J Pharm Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1182\/blood-2008-07-171389","volume":"113","author":"Golden E.B.","year":"2009","unstructured":"Golden E.B.; Lam P.Y.; Kardosh A.; Gaffney K.J.; Cadenas E.; Louie S.G.; Petasis N.A.; Chen T.C.; Sch&#xF6;nthal A.H.; Green tea poly-phenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009,113(23),5927-5937","journal-title":"Blood"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1039\/C1MD00260K","volume":"3","author":"Pamu S.","year":"2012","unstructured":"Pamu S.; Chen D.; Morin F.; Huo C.; Cui Q.; Dou Q.P.; Chan T.H.; Inhibitory effect of bortezomib on human multiple myeloma cells when combined with epigallocatechin-gallate (EGCG) analogs. MedChemComm 2012,3(2),229-232","journal-title":"MedChemComm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1039\/C4OB02512A","volume":"13","author":"Glynn S.J.","year":"2015","unstructured":"Glynn S.J.; Gaffney K.J.; Sainz M.A.; Louie S.G.; Petasis N.A.; Molecular characterization of the boron adducts of the proteasome in-hibitor bortezomib with epigallocatechin-3-gallate and related polyphenols. Org Biomol Chem 2015,13(13),3887-3899","journal-title":"Org Biomol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"15270","DOI":"10.1038\/srep15270","volume":"5","author":"Modernelli A.","year":"2015","unstructured":"Modernelli A.; Naponelli V.; Giovanna Troglio M.; Bonacini M.; Ramazzina I.; Bettuzzi S.; Rizzi F.; EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism. Sci Rep 2015,5(1),15270","journal-title":"Sci Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1182\/blood-2009-03-204776","volume":"113","author":"Shah J.J.","year":"2009","unstructured":"Shah J.J.; Kuhn D.J.; Orlowski R.Z.; Bortezomib and EGCG: no green tea for you? Blood 2009,113(23),5695-5696","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/blood-2008-04-150227","volume":"112","author":"Liu F.T.","year":"2008","unstructured":"Liu F.T.; Agrawal S.G.; Movasaghi Z.; Wyatt P.B.; Rehman I.U.; Gribben J.G.; Newland A.C.; Jia L.; Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008,112(9),3835-3846","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.1021\/acsomega.0c01818","volume":"5","author":"Salehi B.","year":"2020","unstructured":"Salehi B.; Machin L.; Monzote L.; Sharifi-Rad J.; Ezzat S.M.; Salem M.A.; Merghany R.M.; El Mahdy N.M.; K\u0131l\u0131&#xE7;, C.S.; Sytar, O.; Sharifi-Rad, M.; Sharopov, F.; Martins, N.; Martorell, M.; Cho, W.C. Therapeutic potential of quercetin: New insights and perspectives for human health. ACS Omega 2020,5(20),11849-11872","journal-title":"ACS Omega"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1365-2141.2009.07752.x","volume":"146","author":"Kim T.Y.","year":"2009","unstructured":"Kim T.Y.; Park J.; Oh B.; Min H.J.; Jeong T.S.; Lee J.H.; Suh C.; Cheong J.W.; Kim H.J.; Yoon S.S.; Park S.B.; Lee D.S.; Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br J Haematol 2009,146(3),270-281","journal-title":"Br J Haematol"},{"key":"ref=15","first-page":"206","volume":"10","author":"Jia L.","year":"2013","unstructured":"Jia L.; Liu F.T.; Why bortezomib cannot go with \u2018green\u2019? Cancer Biol Med 2013,10(4),206-213","journal-title":"Cancer Biol Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.maturitas.2010.01.010","volume":"66","author":"Prasain J.K.","year":"2010","unstructured":"Prasain J.K.; Carlson S.H.; Wyss J.M.; Flavonoids and age-related disease: risk, benefits and critical windows. Maturitas 2010,66(2),163-171","journal-title":"Maturitas"},{"key":"ref=17","first-page":"1267","volume":"15","author":"Bernstein B.J.","year":"2001","unstructured":"Bernstein B.J.; Grasso T.; Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Williston Park) 2001,15(10),1267-1272","journal-title":"Oncology (Williston Park)"},{"key":"ref=18","author":"Sak K.","year":"2019","unstructured":"Sak K.;  Plant Flavonoids Affects Cancer Chemotherapeutic Efficacy: A Handbook for Doctors and Patients 2019","journal-title":"Plant Flavonoids Affects Cancer Chemotherapeutic Efficacy: A Handbook for Doctors and Patients"},{"key":"ref=19","author":"Sak K.","year":"2019","unstructured":"Sak K.;  Dietary Flavonoids Interfere with Cancer Radiotherapy 2019","journal-title":"Dietary Flavonoids Interfere with Cancer Radiotherapy"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/01635581.2019.1681480","volume":"72","author":"Sak K.","year":"2020","unstructured":"Sak K.; Radiosensitizing potential of curcumin in different cancer models. Nutr Cancer 2020,72(8),1276-1289","journal-title":"Nutr Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00280-011-1591-2","volume":"68","author":"Bannerman B.","year":"2011","unstructured":"Bannerman B.; Xu L.; Jones M.; Tsu C.; Yu J.; Hales P.; Monbaliu J.; Fleming P.; Dick L.; Manfredi M.; Claiborne C.; Bolen J.; Kupperman E.; Berger A.; Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallo-catechin gallate, a component of green tea. Cancer Chemother Pharmacol 2011,68(5),1145-1154","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1021\/jo01088a011","volume":"24","author":"Lorand J.P.","year":"1959","unstructured":"Lorand J.P.; Edwards J.O.; Polyol complexes and structure of the benzeneboronate ion. J Org Chem 1959,24(6),769-774","journal-title":"J Org Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1016\/S0040-4020(02)00489-1","volume":"58","author":"Springsteen G.","year":"2002","unstructured":"Springsteen G.; Wang B.; A detailed examination of boronic acid-diol complexation. Tetrahedron 2002,58(26),5291-5300","journal-title":"Tetrahedron"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s10147-007-0695-5","volume":"12","author":"Tobinai K.","year":"2007","unstructured":"Tobinai K.; Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 2007,12(5),318-326","journal-title":"Int J Clin Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1517\/17425255.4.5.639","volume":"4","author":"Terpos E.","year":"2008","unstructured":"Terpos E.; Roussou M.; Dimopoulos M.A.; Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol 2008,4(5),639-654","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","volume":"15","author":"Dick L.R.","year":"2010","unstructured":"Dick L.R.; Fleming P.E.; Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010,15(5-6),243-249","journal-title":"Drug Discov Today"},{"key":"ref=27","first-page":"471","volume":"12","author":"Mujtaba T.","year":"2011","unstructured":"Mujtaba T.; Dou Q.P.; Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011,12(67),471-480","journal-title":"Discov Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1039\/c0md00119h","volume":"1","author":"Trippier P.C.","year":"2010","unstructured":"Trippier P.C.; McGuigan C.; Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications. MedChemComm 2010,1(3),183-198","journal-title":"MedChemComm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CMAR.S4555","volume":"1","author":"Laubach J.P.","year":"2009","unstructured":"Laubach J.P.; Mitsiades C.S.; Hideshima T.; Schlossman R.; Chauhan D.; Munshi N.; Ghobrial I.; Carreau N.; Anderson K.C.; Rich-ardson P.G.; Bortezomib in the management of multiple myeloma. Cancer Manag Res 2009,1,107-117","journal-title":"Cancer Manag Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1080\/10428194.2018.1523398","volume":"60","author":"Xie J.","year":"2019","unstructured":"Xie J.; Wan N.; Liang Z.; Zhang T.; Jiang J.; Ixazomib - the first oral proteasome inhibitor. Leuk Lymphoma 2019,60(3),610-618","journal-title":"Leuk Lymphoma"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","volume":"19","author":"Richardson P.G.","year":"2018","unstructured":"Richardson P.G.; Zweegman S.; O\u2019Donnell E.K.; Laubach J.P.; Raje N.; Voorhees P.; Ferrari R.H.; Skacel T.; Kumar S.K.; Lonial S.; Ixazomib for the treatment of multiple myeloma. Expert Opin Pharmacother 2018,19(17),1949-1968","journal-title":"Expert Opin Pharmacother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN esti-mates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.2217\/fon-2017-0710","volume":"14","author":"Touzeau C.","year":"2018","unstructured":"Touzeau C.; Moreau P.; Ixazomib in the management of relapsed multiple myeloma. Future Oncol 2018,14(20),2013-2020","journal-title":"Future Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","volume":"11","author":"Zanwar S.","year":"2018","unstructured":"Zanwar S.; Abeykoon J.P.; Kapoor P.; Ixazomib: a novel drug for multiple myeloma. Expert Rev Hematol 2018,11(10),761-771","journal-title":"Expert Rev Hematol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10565-013-9248-z","volume":"29","author":"Vlachostergios P.J.","year":"2013","unstructured":"Vlachostergios P.J.; Voutsadakis I.A.; Papandreou C.N.; Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma. Cell Biol Toxicol 2013,29(4),199-211","journal-title":"Cell Biol Toxicol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00109-011-0805-8","volume":"90","author":"Befani C.D.","year":"2012","unstructured":"Befani C.D.; Vlachostergios P.J.; Hatzidaki E.; Patrikidou A.; Bonanou S.; Simos G.; Papandreou C.N.; Liakos P.; Bortezomib repress-es HIF-1&#x3B1; protein expression and nuclear accumulation by inhibiting both PI3K\/Akt\/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) 2012,90(1),45-54","journal-title":"J Mol Med (Berl)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1021\/mp2004143","volume":"9","author":"Berkers C.R.","year":"2012","unstructured":"Berkers C.R.; Leestemaker Y.; Schuurman K.G.; Ruggeri B.; Jones-Bolin S.; Williams M.; Ovaa H.; Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib. Mol Pharm 2012,9(5),1126-1135","journal-title":"Mol Pharm"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/2040620717710171","volume":"8","author":"Brayer J.","year":"2017","unstructured":"Brayer J.; Baz R.; The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol 2017,8(7),209-220","journal-title":"Ther Adv Hematol"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112270","volume":"195","author":"Plescia J.","year":"2020","unstructured":"Plescia J.; Moitessier N.; Design and discovery of boronic acid drugs. Eur J Med Chem 2020,195","journal-title":"Eur J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.3390\/molecules25184323","volume":"25","author":"Silva M.P.","year":"2020","unstructured":"Silva M.P.; Saraiva L.; Pinto M.; Sousa M.E.; Boronic acids and their derivatives in medicinal chemistry: Synthesis and biological appli-cations. Molecules 2020,25(18),4323","journal-title":"Molecules"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","volume":"179","author":"Fernandes G.F.S.","year":"2019","unstructured":"Fernandes G.F.S.; Denny W.A.; Dos Santos J.L.; Boron in drug design: Recent advances in the development of new therapeutic agents. Eur J Med Chem 2019,179,791-804","journal-title":"Eur J Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.4155\/fmc.09.71","volume":"1","author":"Baker S.J.","year":"2009","unstructured":"Baker S.J.; Ding C.Z.; Akama T.; Zhang Y.K.; Hernandez V.; Xia Y.; Therapeutic potential of boron-containing compounds. Future Med Chem 2009,1(7),1275-1288","journal-title":"Future Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2019.1596258","volume":"28","author":"Smolewski P.","year":"2019","unstructured":"Smolewski P.; Rydygier D.; Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opin Investig Drugs 2019,28(5),421-433","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","volume":"76","author":"Shirley M.","year":"2016","unstructured":"Shirley M.; Ixazomib: First global approval. Drugs 2016,76(3),405-411","journal-title":"Drugs"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009622666220516102235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204810\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009622666220516102235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T07:02:20Z","timestamp":1662793340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204810\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,8,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009622666220516102235","relation":{},"ISSN":["1568-0096"],"issn-type":[{"type":"print","value":"1568-0096"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}